Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Original Article

Galectin-3 inhibits cardiac contractility via a tumor necrosis factor alpha-dependent mechanism in cirrhotic rats

Ki Tae Yoon, Hongqun Liu, Jing Zhang, Sojung Han, Samuel S. Lee

Clin Mol Hepatol. 2022;28(2):232-241. Published online January 5, 2022

DOI: https://doi.org/10.3350/cmh.2021.0141

View: 4610 Download: 106 Web of Science: 4 Crossref: 6

Case Report

Two cases of telbivudine-induced myopathy in siblings with chronic hepatitis B

Eun Hye Kim, Hana Park, Kun Ho Lee, Sang Hoon Ahn, Seung-Min Kim, Kwang-Hyub Han

Clin Mol Hepatol. 2013;19(1):82-86. Published online March 25, 2013

DOI: https://doi.org/10.3350/cmh.2013.19.1.82

View: 6749 Download: 84 Web of Science: 8 Crossref: 10

Original Article

Dobutamine stress echocardiography for evaluating cirrhotic cardiomyopathy in liver cirrhosis

Moon Young Kim, Soon Koo Baik, Chan Sik Won, Hong Jun Park, Hyo Keun Jeon, Hyun Il Hong, Jae Woo Kim, Hyun Soo Kim, Sang Ok Kwon, Jang Young Kim, Byung Su Yoo, Seung Hwan Lee

Clin Mol Hepatol. 2010;16(4):376-382. Published online December 31, 2010

DOI: https://doi.org/10.3350/kjhep.2010.16.4.376

View: 7945 Download: 78 Crossref: 26

3

Long-term clevudine therapy in nucleos(t)ide-naive and Lamivudine-experienced patients with hepatitis B virus-related chronic Liver diseases

Heon Ju Lee, M.D., Jong Ryul Eun, M.D., Chang Hyeong Lee, M.D. Jae Seok Hwang, M.D. Jeong Ill Suh, M.D. Byung Seok Kim, M.D. Byoung Kuk Jang, M.D. Departments of

Clin Mol Hepatol. 2009;15(2):179-192. Published online June 30, 2009

DOI: https://doi.org/10.3350/kjhep.2009.15.2.179

View: 5552 Download: 32 Crossref: 12

1

Clevudine therapy in patients with chronic hepatitis B

Kwan Sik Lee

Clin Mol Hepatol. 2009;15(2):119-121. Published online June 30, 2009

DOI: https://doi.org/10.3350/kjhep.2009.15.2.119

View: 4052 Download: 22 Crossref: 2

2

Cirrhotic Cardiomyopathy

Moon Young Kim , Soon Koo Baik

Clin Mol Hepatol. 2007;13(1):20-26. Published online January 1, 1970

View: 2805 Download: 44

1 |

Viewed By 5168	Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment
Viewed By 5026	MAFLD: How is it different from NAFLD?
Viewed By 4972	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 3646	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Viewed By 3603	Global incidence and prevalence of nonalcoholic fatty liver disease

Cited By 114	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 103	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 76	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 65	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach
Cited By 51	MAFLD: How is it different from NAFLD?

Search